CytRx Co. (OTCMKTS:CYTR) Sees Significant Increase in Short Interest

CytRx Co. (OTCMKTS:CYTRGet Rating) was the recipient of a significant increase in short interest in March. As of March 31st, there was short interest totalling 34,600 shares, an increase of 41.2% from the March 15th total of 24,500 shares. Based on an average daily trading volume, of 168,700 shares, the short-interest ratio is currently 0.2 days.

Shares of OTCMKTS CYTR opened at $0.18 on Friday. The firm’s 50 day moving average price is $0.38 and its 200-day moving average price is $0.50. The company has a market cap of $7.83 million, a PE ratio of -1.20 and a beta of 1.96. CytRx has a 52-week low of $0.17 and a 52-week high of $4.70.

About CytRx (Get Rating)

CytRx Corporation, a biopharmaceutical research and development company, focuses on oncology and rare diseases. It engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor.

Featured Stories

Receive News & Ratings for CytRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytRx and related companies with MarketBeat.com's FREE daily email newsletter.